JP2008533186A - 腸炎治療のためのマクロライド類の使用 - Google Patents
腸炎治療のためのマクロライド類の使用 Download PDFInfo
- Publication number
- JP2008533186A JP2008533186A JP2008502380A JP2008502380A JP2008533186A JP 2008533186 A JP2008533186 A JP 2008533186A JP 2008502380 A JP2008502380 A JP 2008502380A JP 2008502380 A JP2008502380 A JP 2008502380A JP 2008533186 A JP2008533186 A JP 2008533186A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- treatment
- acceptable salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims description 19
- 239000003120 macrolide antibiotic agent Substances 0.000 title description 14
- 229940041033 macrolides Drugs 0.000 title description 5
- 208000004232 Enteritis Diseases 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 12
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 8
- -1 1-oxoethyl Chemical group 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 description 12
- 206010009887 colitis Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 150000003873 salicylate salts Chemical class 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003684 drug solvent Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 0 CC[C@@](C1)([C@]1(C)[C@@]([C@@](C)[C@]([C@](C)C[C@](C)([C@@]([C@@](C)[C@@]([C@@]1C)O)O[C@@]([C@]2O)O[C@](C)C[C@@]2I)O*)O)O)OC1=O Chemical compound CC[C@@](C1)([C@]1(C)[C@@]([C@@](C)[C@]([C@](C)C[C@](C)([C@@]([C@@](C)[C@@]([C@@]1C)O)O[C@@]([C@]2O)O[C@](C)C[C@@]2I)O*)O)O)OC1=O 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102244 | 2005-03-21 | ||
| PCT/EP2006/060709 WO2006100195A1 (en) | 2005-03-21 | 2006-03-14 | Use of macrolides for treating intestinal inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008533186A true JP2008533186A (ja) | 2008-08-21 |
| JP2008533186A5 JP2008533186A5 (enExample) | 2008-12-18 |
Family
ID=36649815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502380A Pending JP2008533186A (ja) | 2005-03-21 | 2006-03-14 | 腸炎治療のためのマクロライド類の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080249034A1 (enExample) |
| EP (1) | EP1868619A1 (enExample) |
| JP (1) | JP2008533186A (enExample) |
| CN (1) | CN101212980A (enExample) |
| AU (1) | AU2006226381B2 (enExample) |
| BR (1) | BRPI0614009A2 (enExample) |
| CA (1) | CA2601640C (enExample) |
| EA (1) | EA012309B1 (enExample) |
| IT (1) | ITMI20060460A1 (enExample) |
| MX (1) | MX2007011544A (enExample) |
| WO (1) | WO2006100195A1 (enExample) |
| ZA (1) | ZA200708423B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1907406B1 (en) | 2005-07-06 | 2010-04-28 | ZAMBON S.p.A. | Crystalline forms of macrolide compounds endowed with antiinflammatory activity |
| WO2008065636A2 (en) * | 2006-12-01 | 2008-06-05 | University College York - National University Of Ireland, Cork | Treatment of disease by modulating cf5 protein |
| WO2022183012A1 (en) * | 2021-02-26 | 2022-09-01 | Pantheryx, Inc. | Stabilized colostrum compositions |
| CN113209084A (zh) * | 2021-05-18 | 2021-08-06 | 南开大学 | 化合物cp0119在制备用于治疗炎性肠病的药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000512653A (ja) * | 1996-06-18 | 2000-09-26 | アボツト・ラボラトリーズ | 大環状１３員環エリスロマイシンａ及びｂの誘導体 |
| WO2004013153A2 (en) * | 2002-08-01 | 2004-02-12 | Zambon Group S.P.A. | Macrolide compounds endowed with antiinflammatory activity |
| JP2004518670A (ja) * | 2001-01-09 | 2004-06-24 | プリバ デイオニツコ ドルストヴオ | 抗炎症治療の改良された細胞標的指向化用の免疫細胞特異的マクロライド化合物と抗炎症性化合物との複合体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2089219C1 (ru) * | 1994-02-22 | 1997-09-10 | Александра Леонидовна Бурмистрова | Способ лечения неспецифического язвенного колита |
| US6551632B2 (en) * | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| IT1306205B1 (it) * | 1999-01-15 | 2001-05-30 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| ITMI20040124A1 (it) * | 2004-01-29 | 2004-04-29 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria |
-
2005
- 2005-03-14 US US11/908,550 patent/US20080249034A1/en not_active Abandoned
-
2006
- 2006-03-14 BR BRPI0614009-2A patent/BRPI0614009A2/pt not_active IP Right Cessation
- 2006-03-14 EP EP06725052A patent/EP1868619A1/en not_active Withdrawn
- 2006-03-14 CA CA2601640A patent/CA2601640C/en not_active Expired - Fee Related
- 2006-03-14 MX MX2007011544A patent/MX2007011544A/es not_active Application Discontinuation
- 2006-03-14 JP JP2008502380A patent/JP2008533186A/ja active Pending
- 2006-03-14 WO PCT/EP2006/060709 patent/WO2006100195A1/en not_active Ceased
- 2006-03-14 EA EA200702036A patent/EA012309B1/ru not_active IP Right Cessation
- 2006-03-14 AU AU2006226381A patent/AU2006226381B2/en not_active Ceased
- 2006-03-14 CN CNA2006800126183A patent/CN101212980A/zh active Pending
- 2006-03-15 IT IT000460A patent/ITMI20060460A1/it unknown
-
2007
- 2007-10-02 ZA ZA200708423A patent/ZA200708423B/xx unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000512653A (ja) * | 1996-06-18 | 2000-09-26 | アボツト・ラボラトリーズ | 大環状１３員環エリスロマイシンａ及びｂの誘導体 |
| JP2004518670A (ja) * | 2001-01-09 | 2004-06-24 | プリバ デイオニツコ ドルストヴオ | 抗炎症治療の改良された細胞標的指向化用の免疫細胞特異的マクロライド化合物と抗炎症性化合物との複合体 |
| WO2004013153A2 (en) * | 2002-08-01 | 2004-02-12 | Zambon Group S.P.A. | Macrolide compounds endowed with antiinflammatory activity |
Non-Patent Citations (1)
| Title |
|---|
| メルクマニュアル 第１７版 日本語版、日経BP社、1999年12月10日発行、P.305-315, JPN6011057309, ISSN: 0002057736 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007011544A (es) | 2008-03-11 |
| ITMI20060460A1 (it) | 2006-09-22 |
| CA2601640A1 (en) | 2006-09-28 |
| AU2006226381B2 (en) | 2011-09-08 |
| WO2006100195A1 (en) | 2006-09-28 |
| BRPI0614009A2 (pt) | 2011-03-01 |
| EA012309B1 (ru) | 2009-08-28 |
| AU2006226381A1 (en) | 2006-09-28 |
| US20080249034A1 (en) | 2008-10-09 |
| CN101212980A (zh) | 2008-07-02 |
| ZA200708423B (en) | 2009-03-25 |
| CA2601640C (en) | 2013-10-22 |
| EA200702036A1 (ru) | 2008-02-28 |
| EP1868619A1 (en) | 2007-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5814625A (en) | Chemoprevention of metachronous adenomatous colorectal polyps | |
| US5945411A (en) | Chemoprevention of metachronous adenomatous colorectal polyps | |
| EP1031350A1 (en) | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain | |
| JP7783743B2 (ja) | 硫酸コンドロイチン多糖類、その半合成調製方法および使用 | |
| TW585762B (en) | Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases | |
| CN117398395B (zh) | 失碳熊去氧胆酸小檗碱盐在制备预防和/或治疗消化道炎症的药物中的用途 | |
| WO2001056568A1 (en) | Remedies or preventives for digestive diseases containing diaminotrifluoromethylpyridine derivatives | |
| JP2008533186A (ja) | 腸炎治療のためのマクロライド類の使用 | |
| EP0811376A1 (en) | Use of alkanoyl L-carnitines for the manufacture of a medicament for the treatment of chronic inflammatory bowel diseases | |
| EP2184284B1 (en) | Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient | |
| CN110652510B (zh) | 中乌宁在制备防治肾纤维化药物中的应用 | |
| JP2018108993A (ja) | 注腸剤 | |
| US10471005B2 (en) | Low dose pharmaceutical composition | |
| CN105079012B (zh) | 天麻素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| CN105147661B (zh) | 升麻素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| JP3587247B2 (ja) | 炎症性腸疾患の予防・治療剤 | |
| US20250262165A1 (en) | Compositions and methods for treating bile acid malabsorption | |
| PT2123277E (pt) | Agente preventivo ou terapêutico para doenças inflamatórias do intestino | |
| CN101039681B (zh) | 肠息肉抑制剂 | |
| CN118178365A (zh) | 石斛酚及其组合物在制备预防和/或治疗消化道炎症的药物或功能食品中的应用 | |
| JP5410816B2 (ja) | 小腸粘膜障害の予防・治療薬剤としての医薬組成物 | |
| US20080076827A1 (en) | Treatment of Inflammatory Bowel Disease | |
| JP2000080030A (ja) | 肉芽腫予防・治療剤 | |
| JP2003119144A (ja) | 胆汁酸誘導体を有効成分とする大腸癌予防／治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081027 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081027 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111215 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120228 |